In this excerpt, taken from his  presentation on the mental health consequences of COVID-19 for 2020NEIMax!, Dr. Sauve' addresses the rise in substance use disorders, and domestic violence as a result of the 2020 pandemic.  Dr. William M. Sauvé received his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, and completed his residency in adult psychiatry at the National Capitol Consortium in Washington, DC, prior to deploying to the Al Anbar Province, Iraq, as the Regimental Psychiatrist for the 7th Marines. After eleven years of active duty service, Dr. Sauvé left the United States Navy to become the Clinical Director of the Military Program at Poplar Springs Hospital in Petersburg, VA, an inpatient structured program for the treatment of Posttraumatic Stress Disorder and Chemical Dependency that caters exclusively to the military population. In 2014, he left Poplar Springs Hospital to focus on Transcranial Magnetic Stimulation and now serves as the Regional Medical Director, Virginia; Greenbrook TMS NeuroHealth Centers and the Medical Director for TMS NeuroHealth Centers in Richmond (Glen Allen) and Charlottesville, VA. Dr. Sauvé also consults for pharmaceutical companies and associated industries as well. He is a member of the American Psychiatric Association, and certified by the American Board of Psychiatry and Neurology. Dr. Sauvé also recently co-authored “Psychopharmacological Treatment,” with Dr. Stahl, a chapter in Treating PTSD in Military Personnel, edited by Bret Moore and Walter Penk.

We know that the COVID-19 pandemic has had a significant impact on mental health around the world. Can you share some findings with us on the effect of COVID-19 on mood disorders from the CLIMB study that was conducted this year? What were some of the new FDA approvals for medications that happened this year? In this episode, Dr, Cutler addresses these questions and so much more, as we take a look back at this year in psychopharmacology. Dr. Andrew J. Cutler is Chief Medical Officer at the Neuroscience Education Institute, and Clinical Professor in the Department of Psychiatry at SUNY Upstate Medical University, Syracuse, NY Dr. Cutler has been Principal Investigator (PI) on over 400 psychiatric and medical clinical trials. He has authored over 50 peer-reviewed scientific articles and has authored and presented over 100 abstracts/posters at various scientific meetings. He serves as a peer reviewer for many prestigious scientific and medical journals and serves or has served on several Editorial Boards. He has chaired or attended over 200 Scientific Advisory Boards, delivered over 3,000 pharmaceutical promotional talks and over 250 invited CME lectures and Grand Rounds presentations. He has also done over 30 national satellite television medical education broadcasts and over 100 national medical web conferences. Dr. Cutler is a member of several professional organizations, including the American Psychiatric Association, the Florida Psychiatric Society and the American Medical Association. He has earned the Certified Physician Investigator (CPI) distinction from the Academy of Physicians in Clinical Research (formerly the Academy of Pharmaceutical Physicians and Investigators). He is a Fellow of the American Psychiatric Association and the Academy of Psychosomatic Medicine. He has received several professional honors and awards including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the American Psychiatric Association, the Outstanding Congressional Fellow Award from the 103rd U.S. Congress, a citation from Florida Hospital for outstanding patient care and the Distinguished Clinical Professional Award from the Mental Health Association of Central Florida. He presents research posters and teaches at professional meetings and has published numerous articles in scientific and medical journals. Dr. Cutler frequently gives talks to community groups and national audiences, and often appears as a medical expert in the local and national media.  

Neurodegenerative disorders have become increasingly prevalent today and can often be accompanied by dementia and other neuropsychiatric conditions such as psychosis. It is important to be able to differentiate psychosis that is associated with various types of dementia, while this can be challenging to clinicians. However, there are several existing and novel therapeutics that can manage dementia-related psychosis. In this episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo on the practical strategies for the management of dementia-related psychosis. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-DemPsychosis Learning Objectives: After completing this educational activity, you should be better able to: Describe the clinical presentation of psychosis in dementia Employ pharmacological treatment strategies to ameliorate psychosis in patients with dementia Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by a PhD specializing in neurodegenerative diseases to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Laxman Bhagwan Bahroo, DO Associate Professor and Residency Program Director, Department of Neurology; Director, Botulinum Toxin Clinic; MedStar Georgetown University Hospital Pasquerilla Healthcare Center, Washington, DC Consultant/Advisor: AbbVie, Acadia, Acorda, Allergan, Amneal, Neurocrine, Revance, Sunovion, US World Meds Speakers Bureau: AbbVie, Acadia, Acorda, Adamas, Allergan, Amneal, Ipsen, Neurocrine, Sunovion, UCB, US World Meds Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture  Support: This activity is supported by an unrestricted educational grant from Acadia Pharmaceuticals. Released: December 14, 2020     CME credit expires: December 14, 2023

Despite increasing evidence that bipolar disorders often emerge in adolescence, only about half of adolescents with a bipolar disorder receive mental health care. Research has shown that an early onset of a bipolar disorder, concomitant with a poor diagnosis and lack of treatment, can have lifelong devastating effects for the patient. Adults and younger people who initially exhibit symptoms only of depression may later develop bipolar disorder. The risk of depression turning into bipolar disorder is estimated at 10 percent or less in adults but appears to be as high as 20–40 percent in children and adolescents. In this episode, Dr. Neera Ghaziuddin answers many questions regarding how to better diagnosis and treat pediatric bipolar disorder, and depression with mixed features in the pediatric population. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-PedBip Learning Objectives: After completing this educational activity, you should be better able to: Discuss challenges to diagnosing bipolar disorder in the pediatric population (e.g. adolescents) Define the concept of “mixed features” according to different diagnostic criteria Improve the differential diagnosis of depression with mixed features (DMX) in children and adolescents Utilize evidence-based therapies in the treatment of pediatric patients presenting with DMX Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in pediatric psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Neera Ghaziuddin, MD, MRCPsych Professor, Child and Adolescent Psychiatry Unit, Department of Psychiatry, University of Michigan Medical School, Ann Arbor, MI No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found at https://nei.global/culture. Support: This activity is supported by an unrestricted educational grant from Sunovion. Released: December 3, 2020     CME credit expires: December 3, 2023

How can someone tell whether they are experiencing chronic levels of stress? The holidays are typically a great source of stress for most people. What are the unique challenges that we face this year in terms of the holidays during a pandemic? In this timely interview, Dr. Jennifer Love addresses these important questions, and so much more in this episode. With the release of her upcoming book, “When Crisis Strikes” she shares some powerful tips on detecting and managing chronic stress. Dr. Jennifer Love is board-certified in psychiatry, addiction psychiatry and addiction medicine, and is a Diplomate of the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. She practices at a large clinic in Southern California. Dr. Love is an award-winning researcher and international speaker, interested in the interface between cultural and spiritual factors and overall mental health. Dr. Love’s work focuses on restoring life balance, brain and body health, and helping her patients improve their functionality and satisfaction in life. She considers a wide range of interventions including nutraceuticals, medication, exercise, yoga, psychotherapy, and sleep/relaxation training. Her specialties include: mood disorders, substance-use disorders, anxiety disorders, anger and irritability, behavioral addictions, co-occurring pain and opioid dependence. Dr. Love is the co-author of When Crisis Strikes: 5 Steps to Heal Your Brain, Body, and Life from Chronic Stress. Stay up to date by following @dr_author_jennifer_love on Instagram.        

Tardive dyskinesia (TD) is a movement disorder characterized by involuntary movements of the tongue, lips, face, trunk, and extremities that occur in patients treated with dopamine receptor blocking agents (DRBAs). Patients can have symptoms that persist for months, years, or even permanently. Greater awareness about risk factors and which agents may be associated with higher likelihood of developing TD is critical to reduce the prevalence of this disorder. Understanding the most effective novel treatment approaches to TD is also important. In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the current best practices in the diagnosis, recognition, and treatment of tardive dyskinesia.  Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-TD  Learning Objectives: After completing this educational activity, you should be better able to: Identify the clinical presentation of tardive dyskinesia Implement treatment strategies for the management of tardive dyskinesia  Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics.  Peer Review: The content was peer-reviewed by a PhD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris  Interviewee Jonathan M. Meyer, MD Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: Acadia, Alkermes, Allergan, Intra-Cellular Therapies, Neurocrine Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Neurocrine, Otsuka, Sunovion, Teva  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported by an unrestricted educational grant from Neurocrine Continental, Inc.  Released: November 19, 2020          CME credit expires: November19, 2023

What are the most common reasons for insomnia? What is effective for treating insomnia? Can you explain sleep hygiene? In Part 2 she answers these questions and so much more! Dr. Jade Wu is a licensed clinical psychologist, sleep researcher, and host of the Savvy Psychologist podcast. She is a frequent guest on popular radio and podcast shows such as NPR, and quoted in popular press publications like New York Times, NBC News, and Huffington Post. Her current research focuses on treating sleep disorders in those with chronic illness. In the clinic, Dr. Wu uses evidence-based non-medication treatments to help people improve their sleep (and wake). Her approach is grounded in both science and compassion, so that her clients are empowered to live healthier and more fulfilled lives.  My website: www.JadeWuPhD.com Twitter: @JadeWuPhD Resources can be found on her website under the "Resources" tab.

Join us for this important extended Q&A session with psychiatric nurse practitioner; Deb York, in which she answers your most pressing questions from her presentation on early life childhood adversity.

Join us for a fascinating extended Q&A with Dr. William Sauve’ where he addresses your unanswered questions from his presentation on the mental health consequences of COVID-19.

In this episode, listen in for an extended Q&A session with Dr. Jeffrey Strawn as he answers your most pressing questions from his presentation on treating refractory anxiety disorders.